[1]姚媛媛 张鑫 叶润宇 陈晓平.难治性高血压的认识和治疗进展[J].心血管病学进展,2024,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.007]
　YAO Yuanyuan,ZHANG Xin,YE Runyu,et al.Recognition and Treatment of Resistant Hypertension[J].Advances in Cardiovascular Diseases,2024,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.007]
点击复制

难治性高血压的认识和治疗进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年12期
页码:
1084
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
Recognition and Treatment of Resistant Hypertension
作者:
姚媛媛 张鑫 叶润宇 陈晓平
?四川大学华西医院心脏内科,四川 成都 610041)
Author(s):
YAO Yuanyuan; ZHANG Xin; YE Runyu; CHEN Xiaoping
(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)
关键词:
难治性高血压; 定义; 流行病学; 机制; 治疗
Keywords:
Resistant hypertension;  Definition;  Epidemiology;  Mechanisms;  Treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2024.12.007
摘要:
难治性高血压是高血压的重要特殊表型之一，定义为尽管使用3种及以上抗高血压药，血压仍未达到目标值。已有大量证据表明难治性高血压人群具有较高的心血管事件发生率以及全因死亡率，但该特殊人群尚未在临床工作中得到广泛重视及充分管理。现就难治性高血压的定义、流行病学、相关机制及治疗进展做简要综述，以便临床医生规范管理该类人群。
Abstract:
Resistant hypertension is one of the important specific phenotypes of hypertension,which defined as uncontrolled blood pressure despite treatment with at least three or more antihypertensive agents. Compelling evidence has shown that such a population has a greater risk of cardiovascular events as well as mortality. However,it has not yet been widely emphasized and adequately managed in clinic. In the article,we provide a brief review on the definition,epidemiology,related mechanisms and treatment options of resistant hypertension,so that clinicians can standardize the management of this population

参考文献/References:

[1] Brouwers S,Sudano I,Kokubo Y,et al. Arterial hypertension[J]. Lancet,2021,398(10296):249-261.

[2] Carey RM,Calhoun DA,Bakris GL,et al. Resistant hypertension: detection,evaluation,and management:a scientific statement from the American Heart Association[J]. Hypertension,2018,72(5):e53-e90.

[3] Matanes F,Khan MB,Siddiqui M,et al. An update on refractory hypertension[J]. Curr Hypertens Rep,2022,24(7):225-234.

[4] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension:Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.

[5] Noubiap JJ,Nansseu JR,Nyaga UF,et al. Global prevalence of resistant hypertension:a meta-analysis of data from 3.2 million patients[J]. Heart,2019,105(2):98-105.

[6] Abiodun OO,Anya T,Chukwu JC,et al. Prevalence,risk factors and cardiovascular comorbidities of resistant hypertension among treated hypertensives in a nigerian population[J]. Glob Heart,2024,19(1):17.

[7] Muxfeldt ES,Chedier B. Refractory hypertension:what do we know so far?[J]. J Hum Hypertens,2021,35(3):181-183.

[8] Yoon M,You SC,Oh J,et al. Prevalence and prognosis of refractory hypertension diagnosed using ambulatory blood pressure measurements[J]. Hypertens Res,2022,45(8):1353-1362.

[9] Ebinger JE,Kauko A,Bello NA,et al. Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry[J]. Eur J Prev Cardiol,2023,30(10):960-968.

[10] Bakris G,Chen C,Campbell AK,et al. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus[J]. J Clin Hypertens (Greenwich),2023,25(8):737-747.

[11] Tsujimoto T,Kajio H. Intensive blood pressure treatment for resistant hypertension[J]. Hypertension,2019,73(2):415-423.

[12] Bourque G,Hiremath S. Rethinking resistant hypertension[J]. J Clin Med,2022,11(5):1455.

[13] Gaddam KK,Nishizaka MK,Pratt-Ubunama MN,et al. Characterization of resistant hypertension:association between resistant hypertension,aldosterone,and persistent intravascular volume expansion[J]. Arch Intern Med,2008,168(11):1159-1164.

[14] Beaussier H,Boutouyrie P,Bobrie G,et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence[J]. J Hypertens,2015,33(12):2526-2533.

[15] Bacan G,Ribeiro-Silva A,Oliveira VAS,et al. Refractory hypertension:a narrative systematic review with emphasis on prognosis[J]. Curr Hypertens Reps,2022,24(4):95-106.

[16] Siddiqui M,Bhatt H,Judd E K,et al. Reserpine substantially lowers blood pressure in patients with refractory hypertension:a proof-of-concept study[J]. Am J Hypertens,2020,33(8):741-747.

[17] Blumenthal JA,Hinderliter AL,Smith PJ,et al. Effects of lifestyle modification on patients with resistant hypertension:results of the TRIUMPH randomized clinical trial[J]. Circulation,2021,144(15):1212-1226.

[18] Hornstrup BG,Hoffmann-Petersen N,Lauridsen TG,et al. Dietary sodium restriction reduces blood pressure in patients with treatment resistant hypertension[J]. BMC Nephrology,2023,24(1):274.

[19] Lamirault G,Artifoni M,Daniel M,et al. Resistant hypertension:novel insights[J]. Curr Hypertens Rev,2020,16(1):61-72.

[20] DiNicolantonio JJ,Bhutani J,Lavie CJ,et al. Evidence-based diuretics:focus on chlorthalidone and indapamide[J]. Future Cardiol,2015,11(2):203-217.

[21] Tian Z,Vollmer Barbosa C,Lang H,et al. Efficacy of pharmacological and interventional treatment for resistant hypertension:a network meta-analysis[J]. Cardiovasc Res,2024,120(1):108-119.

[22] Williams B,MacDonald TM,Morant S,et al. Spironolactone versus placebo,bisoprolol,and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):a randomised,double-blind,crossover trial[J]. Lancet,2015,386(10008):2059-2068.

[23] Williams B,MacDonald TM,Morant SV,et al. Endocrine and haemodynamic changes in resistant hypertension,and blood pressure responses to spironolactone or amiloride:the PATHWAY-2 mechanisms substudies[J]. Lancet Diabetes Endocrinol,2018,6(6):464-475.

[24] Krieger EM,Drager LF,Giorgi DMA,et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension:the ReHOT randomized study (resistant hypertension optimal treatment)[J]. Hypertension,2018,71(4):681-690.

[25] Gupta R,Maitz T,Egeler D,et al. SGLT2 inhibitors in hypertension:role beyond diabetes and heart failure[J]. Trends Cardiovasc Med,2023,33(8):479-486.

[26] Wheeler DC,Stefánsson BV,Jongs N,et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:a prespecified analysis from the DAPA-CKD trial[J]. Lancet Diabetes Endocrinol,2021,9(1):22-31.

[27] Ferreira JP,Fitchett D,Ofstad AP,et al. Empagliflozin for patients with presumed resistant hypertension:a post hoc analysis of the EMPA-REG OUTCOME trial[J]. Am J Hypertens,2020,33(12):1092-1101.

[28] Qin J,Wang W,Wei P,et al. Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions:a systematic review and meta-analysis[J]. Front Pharmacol ,2022,13:982372.

[29] Malik AH,Aronow WS. Efficacy of sacubitril/valsartan in hypertension[J]. Am J Ther,2022,29(3):e322-e333.

[30] Jackson AM,Jhund PS,Anand IS,et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J]. Eur Heart J,2021,42(36):3741-3752.

[31] Rivera FB,Lumbang GNO,Gaid DRM,et al. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus:a meta-analysis and meta-regression[J]. Diabetes Obes Metab,2024,26(6):2209-2228.

[32] Hu M,Cai X,Yang W,et al. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus:a meta-analysis[J]. J Am Heart Assoc,2020,9(7):e015323.

[33] Dudenbostel T,Ghazi L,Liu M,et al. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension[J]. Hypertension,2016,68(4):995-1003.

[34] Salvador VD,Bakris GL. Novel antihypertensive agents for resistant hypertension:what does the future hold?[J]. Hypertension Res,2022,45(12):1918-1928.

[35] Schlaich MP,Bellet M,Weber MA,et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION):a multicentre,blinded,randomised,parallel-group,phase 3 trial[J]. Lancet,2022,400(10367):1927-1937.

[36] Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J]. Lancet ,2021,397(10293):2476-2486.

[37] Pisano A,Iannone LF,Leo A,et al. Renal denervation for resistant hypertension[J]. Cochrane Database Syst Rev,2021,11(11):CD011499.

相似文献/References:

[1]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
　ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(12):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[2]晏婉清 吴昕悦 任勇.慢性肾脏病与难治性高血压[J].心血管病学进展,2024,(12):1088.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.008]
　YAN Wanqing,WU Xinyue,REN Yong.Chronic Kidney Disease with Resistant Hypertension[J].Advances in Cardiovascular Diseases,2024,(12):1088.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.008]

更新日期/Last Update: 2025-01-08